

Thursday | 24 October 2024 | 12:00 – 13:00 | Hall B



Cerebroprotection in AIS – New evidence from two different trials

LUNCH
PACKAGE
FOR FREE

Chair: Steven Zeiler (USA)

- **Add-on therapy following MT in patients with embolic stroke**
Ahmed El Bassiouny (Egypt)
- **C-REGS2 – First results of a large high-quality comparative effectiveness study**
Michael Brainin (Austria)

This session is not included in the main event CME/CPD credit.



"Scales Booklet"

Essential Clinical Rating Scales - From acute Stroke to Neurorehabilitation.

Visit our EVER Satellite Symposium and you will receive a quick guide to important rating scales regarding stroke assessment, stroke treatment and stroke rehabilitation outcome.

VISIT US AT BOOTH #15

MEET THE EXPERT SESSIONS

23 October | 12:10 – 12:25

Jacek Staszewski

**Can adding a
cerebroprotective agent to
EVT improve outcome?**

25 October | 9:40 – 9:55

Milan Vosko

**Clinical relevance of
C-REGS2 study**

SMALL MOMENT. BIG DIFFERENCE.

Last month, Paul was suffering from cognitive and motor impairment. Today, he's making his next big move.

- Improvement of motor functions
- Regain full independence
- Early recovery after stroke
- Increase quality of life

Muresanu, et al., 2016

ABBREVIATED PRESCRIBING INFORMATION: Name of the medicinal product: Cerebrolysin® - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of porcine brain-derived peptide preparation (Cerebrolysin® concentrate) in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: Organic, metabolic and neurodegenerative disorders of the brain, especially senile dementia of Alzheimer's type - Post-apoplectic complications - Craniocerebral trauma; post-operative trauma, cerebral contusion or concussion. Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Untertach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.



Cerebrolysin®
Reconnecting Neurons.
Empowering for Life.